On September 7, 2026, the State Administration for Market Regulation investigated and dealt with the act of the Hubei Provincial Health Commission of abusing administrative power to exclude and restrict competition. It was found that in November 2025, the commission arbitrarily established a list of drugs to be encouraged for use, including 26 locally produced drugs, and required medical institutions to purchase and use these drugs as well as to implement ledger management. This act violated Articles 39 and 45 of the Anti-Monopoly Law. Currently, the regulatory agency has issued an administrative recommendation to the Hubei Provincial Government, the list involved has been publicly revoked, and the relevant responsible persons are being held accountable.
The Hubei Provincial Health Commission was legally investigated and punished by the State Administration for Market Regulation for abusing administrative power to eliminate and restrict competition. It was found that in November 2025, the commission arbitrarily established a list of drugs to be encouraged for use, including 26 locally produced drugs. Medical institutions were required to equip themselves with these drugs and implement ledger management; this action violated Articles 39 and 45 of the Anti-Monopoly Law. The regulatory agency has issued an administrative recommendation to the Hubei Provincial Government, and the involved list has been publicly revoked. Relevant responsible persons have been held accountable.